Neurocrine Biosciences, Inc. (LON:0K6R)

Market Cap	7.93B
Revenue (ttm)	1.88B
Net Income (ttm)	272.62M
Shares Out	n/a
EPS (ttm)	2.63
PE Ratio	29.10
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111
Average Volume	1,062
Open	104.90
Previous Close	104.65
Day's Range	104.22 - 107.10
52-Week Range	89.66 - 143.27
Beta	n/a
RSI	54.97
Earnings Date	May 2, 2025

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1992
• Employees: 1,800
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K6R

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.

Financial numbers in USD